Medications Causing Potassium Retention (Hyperkalemia)
Potassium retention is most often caused by medications that impair renal potassium excretion. These include renin–angiotensin–aldosterone system inhibitors, potassium-sparing diuretics, and several other drugs with aldosterone- or renal-tubule–related effects. [1], [2]
Primary Medication Classes
- Renin–angiotensin–aldosterone system inhibitors
- Angiotensin-converting enzyme (ACE) inhibitors (including lisinopril and enalapril). [1], [2]
- Angiotensin II receptor blockers (ARBs) (including losartan and valsartan). [1], [2]
-
Direct renin inhibitors (including aliskiren). [1]
-
Aldosterone suppression or aldosterone blockade
- Mineralocorticoid receptor antagonists (including spironolactone and eplerenone). [1], [2]
-
Potassium-sparing diuretics (including amiloride and triamterene). [1], [2]
-
Medications impairing renal potassium excretion through other mechanisms
- Trimethoprim (including trimethoprim-sulfamethoxazole). [1], [2]
- Heparin. [1], [2]
- Calcineurin inhibitors (including cyclosporine and tacrolimus). [1]
- Nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors (including ibuprofen and naproxen). [1], [2]
- Pentamidine. [1]
Mechanism-Based Selection Framework
- Potassium-sparing or aldosterone-related mechanisms
-
Mineralocorticoid receptor antagonism and potassium-sparing diuretic effects reduce distal nephron potassium secretion. [1], [2]
-
Renin–angiotensin–aldosterone axis inhibition
-
ACE inhibitors and ARBs reduce aldosterone signaling and can decrease urinary potassium excretion. [1], [2]
-
Direct reduction of aldosterone production or action
-
Heparin and calcineurin inhibitors can impair adrenal aldosterone biosynthesis. [1]
-
Effects on tubular regulation of potassium secretion
-
Trimethoprim can impair renal tubular potassium excretion. [1]
-
Reduced renal prostaglandin effects
- NSAIDs can impair potassium excretion by altering renal hemodynamics and aldosterone-related pathways. [1], [2]
Important Clarifications
- Some drugs can increase serum potassium by shifting potassium out of cells rather than by directly retaining potassium. [1]
- Redistribution mechanisms (for example, beta-blocker–related effects in certain contexts) are not the main cause of persistent potassium retention. [1]
Common Pitfalls to Avoid
- Assuming potassium retention risk is limited to potassium supplements is incorrect. [2]
- Assuming that only chronic kidney disease creates risk is incorrect. Drugs that impair potassium excretion can cause clinically significant hyperkalemia even without severe renal impairment. [2]
Monitoring-Relevant High-Risk Contexts
- Concomitant use of multiple potassium-retaining agents increases hyperkalemia risk. [1], [2]
- Renal dysfunction and hypoaldosteronism increase the likelihood of clinically important potassium retention with these medications. [2]
Medication Examples List for Practical Review
- ACE inhibitors (lisinopril, enalapril). [1], [2]
- ARBs (losartan, valsartan). [1], [2]
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone). [1], [2]
- Potassium-sparing diuretics (amiloride, triamterene). [1], [2]
- Direct renin inhibitor (aliskiren). [1]
- Trimethoprim (trimethoprim-sulfamethoxazole). [1], [2]
- Heparin. [1], [2]
- Calcineurin inhibitors (cyclosporine, tacrolimus). [1]
- NSAIDs (ibuprofen, naproxen). [1], [2]
- Pentamidine. [1]